Next Article in Journal
An Integrated Valuation Model for Payer and Investor
Previous Article in Journal
Barriers in Precision Medicine Implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 10
Issue 1
10.1080/20016689.2022.2078474
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cost Comparison of Adverse Event Management among Breast and Ovarian Cancer Patients Treated with Poly (ADP-ribose) Polymerase Inhibitors: Analysis Based on Phase 3 Clinical Trials

by
Lin Fan
1,
Yuanyuan Zhang
2,*,
Peter Maguire
2,
Dominic Muston
1,
Matthew Monberg
3,
Jagadeswara Rao Earla
3,
Adela Mihai
4 and
Poonam Gulati
5
1
Health Economics and Decision Science, Merck & Co., Inc., Rahway, NJ, USA
2
Health Economics and Evidence Generation, Wickenstones Ltd., Units 24 & 26, 127 Olympic Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SA, UK
3
Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ, USA
4
Global Health Economics and Payer Evidence, AstraZeneca PLC, Cambridge, UK
5
Global Regulatory Affairs, AstraZeneca PLC, Cambridge, UK
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2022, 10(1), 2078474; https://doi.org/10.1080/20016689.2022.2078474
Submission received: 28 January 2022 / Revised: 6 May 2022 / Accepted: 12 May 2022 / Published: 8 June 2022

Abstract

Background: The economic impact of adverse events (AEs) for poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated. Objective: Compare PARPi-related AE management costs from a US payer perspective. Methods: The frequency of treatment-related grade 3–4 AEs was obtained from published clinical trials of PARPis for the treatment of advanced ovarian cancer (AOC), platinum-sensitive recurrent ovarian cancer (PSROC), and metastatic breast cancer (MBC). AE management costs per patient (2020 USD) per treatment course were calculated by multiplying the AE unit costs by the frequency of AEs for each arm of each trial. Sensitivity analyses were conducted according to the lower and upper limits of the 95% confidence interval for AE rates and unit costs, respectively. Scenarios were also performed to explore the uncertainty of outcomes. Results: Total AE management costs in AOC were: $3904, olaparib; $5595, olaparib plus bevacizumab; and $12,215, niraparib. In PSROC, total costs were: $3894, olaparib; $6001, rucaparib; and $11,492, niraparib, and in MBC: $3574, olaparib; and $9489, talazoparib. Hematological toxicities were the key drivers of AE management costs for PARPis. Conclusions: The main AEs among PARPis were hematological. Olaparib was associated with lower AE costs compared to other PARPis.
Keywords: cost analysis; PARP inhibitors; adverse event; advanced ovarian cancer; platinum-sensitive recurrent ovarian cancer; metastatic breast cancer cost analysis; PARP inhibitors; adverse event; advanced ovarian cancer; platinum-sensitive recurrent ovarian cancer; metastatic breast cancer

Share and Cite

MDPI and ACS Style

Fan, L.; Zhang, Y.; Maguire, P.; Muston, D.; Monberg, M.; Earla, J.R.; Mihai, A.; Gulati, P. Cost Comparison of Adverse Event Management among Breast and Ovarian Cancer Patients Treated with Poly (ADP-ribose) Polymerase Inhibitors: Analysis Based on Phase 3 Clinical Trials. J. Mark. Access Health Policy 2022, 10, 2078474. https://doi.org/10.1080/20016689.2022.2078474

AMA Style

Fan L, Zhang Y, Maguire P, Muston D, Monberg M, Earla JR, Mihai A, Gulati P. Cost Comparison of Adverse Event Management among Breast and Ovarian Cancer Patients Treated with Poly (ADP-ribose) Polymerase Inhibitors: Analysis Based on Phase 3 Clinical Trials. Journal of Market Access & Health Policy. 2022; 10(1):2078474. https://doi.org/10.1080/20016689.2022.2078474

Chicago/Turabian Style

Fan, Lin, Yuanyuan Zhang, Peter Maguire, Dominic Muston, Matthew Monberg, Jagadeswara Rao Earla, Adela Mihai, and Poonam Gulati. 2022. "Cost Comparison of Adverse Event Management among Breast and Ovarian Cancer Patients Treated with Poly (ADP-ribose) Polymerase Inhibitors: Analysis Based on Phase 3 Clinical Trials" Journal of Market Access & Health Policy 10, no. 1: 2078474. https://doi.org/10.1080/20016689.2022.2078474

APA Style

Fan, L., Zhang, Y., Maguire, P., Muston, D., Monberg, M., Earla, J. R., Mihai, A., & Gulati, P. (2022). Cost Comparison of Adverse Event Management among Breast and Ovarian Cancer Patients Treated with Poly (ADP-ribose) Polymerase Inhibitors: Analysis Based on Phase 3 Clinical Trials. Journal of Market Access & Health Policy, 10(1), 2078474. https://doi.org/10.1080/20016689.2022.2078474

Article Metrics

Back to TopTop